Mainstream

Mineralys signals pre-NDA meeting for lorundrostat in Q4 2025 while expanding clinical programs into cardiorenal comorbidities

Mineralys signals pre-NDA meeting for lorundrostat in Q4 2025 while expanding clinical programs into cardiorenal comorbidities

Post ContentmlysRead More

You might also be interested in reading South Korea’s President Challenges the FSC’s Warning on Bitcoin ETFs.

August 13, 2025
In Mainstream